Literature DB >> 18825412

Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?

Alberto Ravaioli, Stefania Nicoletti, Emiliano Tamburini, Maximilian Papi.   

Abstract

Numerous studies referring to conventional chemotherapy for aggressive fibromatosis with the use of doxorubicin, cyclophosphamide, vincristin, vinblastine and other drugs have been published. Imatinib mesylate is a recently developed oral anticancer agent designed to selectively inhibit tyrosine kinases implicated in oncogenesis and it seems to represent a promising opportunity (also in first line) in the treatment of patients with advanced disease not candidate to prior surgery.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18825412     DOI： 10.1007/s00432-008-0459-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  5 in total

1.  Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.

Authors:  Joseph Mace; J Sybil Biermann; Vernon Sondak; Cornelius McGinn; Curtis Hayes; Dafydd Thomas; Laurence Baker
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

2.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 3.  The pharmacological treatment of aggressive fibromatosis: a systematic review.

Authors:  J Janinis; M Patriki; L Vini; G Aravantinos; J S Whelan
Journal:  Ann Oncol       Date:  2003-02       Impact factor: 32.976

4.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

Review 5.  Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.

Authors:  Gabriel Wcislo; Katarzyna Szarlej-Wcislo; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-24       Impact factor: 4.322
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.